Precigen (PGEN) Expected to Announce Quarterly Earnings on Tuesday

Precigen (NASDAQ:PGEN - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect Precigen to post earnings of ($0.08) per share and revenue of $0.50 million for the quarter.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The business had revenue of $1.19 million during the quarter, compared to analysts' expectations of $1.30 million. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Stock Up 2.6 %

Shares of PGEN stock traded up $0.04 during trading on Friday, reaching $1.39. The company's stock had a trading volume of 228,458 shares, compared to its average volume of 1,263,397. The business has a fifty day moving average price of $1.55 and a 200-day moving average price of $1.28. Precigen has a one year low of $0.65 and a one year high of $2.17. The company has a market cap of $408.80 million, a price-to-earnings ratio of -2.52 and a beta of 1.82.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PGEN. HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Precigen in a research note on Thursday, March 20th. JMP Securities restated a "market outperform" rating and issued a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.